Zepbound (Tirzepatide) Hair Loss That Doesn't Go Away: Causes, Workup, and Next Steps

What the Zepbound label reports

The hair-loss numbers come from a pooled safety population of 2,519 adults treated in the two placebo-controlled weight-management trials for up to 72 weeks, plus a 4-week off-drug follow-up [1]. In that pool, hair loss was reported by 1% of patients on placebo and by 5% on 5 mg, 4% on 10 mg and 5% on 15 mg once weekly [1]. The label counts hair loss among the drug's common adverse reactions [1].

The label adds three details. It describes hair loss as associated with weight reduction. It reports it far more often in women than in men: 7.1% of women versus 0.5% of men on Zepbound, against 1.3% of women and 0% of men on placebo. And no Zepbound-treated patient in the pool stopped treatment because of hair loss, while one placebo-treated patient did [1].

Hair loss was reported at similar rates across the Zepbound dose groups: 5% at 5 mg, 4% at 10 mg and 5% at 15 mg [1].

Telogen effluvium, and the other pattern

Telogen effluvium is diffuse shedding across the scalp, in which a large share of follicles shift into the resting phase together.

A 2026 systematic review screened 133 studies and included 24. It found that semaglutide and tirzepatide had the highest reported rates of hair loss among GLP-1 drugs, that androgenetic alopecia and telogen effluvium were the predominant subtypes reported, and that tirzepatide — the agent producing the largest weight loss — was most frequently linked to telogen effluvium. Women appeared disproportionately affected, and rapid weight loss emerged as a potential contributor, with causality not established [2].

A cross-sectional survey of 254 people using GLP-1 drugs for weight loss, including Mounjaro (tirzepatide), described the hair loss in that group as typically non-scarring and reversible; it did not track regrowth for any individual [4]. Hair-loss prevalence did not differ significantly between products (p=0.116), but severe hair loss was more common among Mounjaro users (43.4%) and Saxenda users (42.9%) than other groups, and men were less likely to report hair loss than women (adjusted odds ratio 0.36) [4].

Spontaneous-reporting analyses of the FDA adverse event database do not agree with each other on tirzepatide: one found a lower, non-significant reporting signal for alopecia with tirzepatide while semaglutide showed one [5], and another found alopecia relatively more frequently reported with tirzepatide than semaglutide [6]. These are reporting patterns, not measures of risk.

Androgenetic alopecia and nutritional causes

Androgenetic alopecia is a distinct diagnosis with its own trial-tested treatments [3].

On nutrition, a review of iron deficiency and hair loss found the evidence insufficient to recommend iron screening for everyone with hair loss, or iron supplements for people with hair loss who have iron deficiency without anemia [8]. A review of vitamin D in non-scarring alopecia found decreased serum 25-hydroxyvitamin D in the majority of studies, which could suggest a role in hair loss, but its authors say larger studies are required [7].

Treatments that have trial evidence

For androgenetic alopecia, a meta-analysis of good- or fair-quality randomized trials found five treatments superior to placebo (P<0.00001): low-level laser therapy in men, 5% minoxidil in men, 2% minoxidil in men, 1 mg finasteride in men, and 2% minoxidil in women [3]. Those trials enrolled people with androgenetic alopecia, not people whose shedding began on tirzepatide.

Low-dose oral minoxidil has been studied as an alternative for people who struggle with topical products. A review found 17 studies with 634 patients, covering mostly androgenetic alopecia plus telogen effluvium and other conditions, and concluded that oral minoxidil was effective and well tolerated in healthy patients who have difficulty with topical formulations. The authors noted that larger randomized trials with standardized measurements are still needed [9].

Dose, stopping and weight regain

The only label statement that speaks to dosing in this situation is general: if a maintenance dose is not tolerated, consider a lower maintenance dose [1]. It is not specific to hair loss.

For context on weight, in SURMOUNT-1 mean weight change at 72 weeks was -15.0% with 5 mg, -19.5% with 10 mg and -20.9% with 15 mg, versus -3.1% with placebo [10]. In SURMOUNT-4, adults who switched to placebo after 36 weeks of tirzepatide regained weight (+14.0%) while those who continued lost a further 5.5% between weeks 36 and 88 [11].